TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03144895

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laying a radial or femoral arterial catheter
Description: Laying a radial or femoral arterial catheter

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laying a radial or femoral arterial catheter
Description: Laying a radial or femoral arterial catheter
Study: NCT01938833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Study: NCT00990821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg MK-0517 (PS80)
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Study: NCT03483974

Intervention type: DIAGNOSTIC_TEST
Intervention: hyperspectral imaging
Description: using hyperspectral detector for evaluation excreta pattern

Intervention type: DIAGNOSTIC_TEST
Intervention: hyperspectral imaging
Description: using hyperspectral detector for evaluation excreta pattern
Study: NCT02201914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Description: patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily FSH and LH plus Cetrorelix
Description: Women receive an initial daily dose of 450 IU recombinant FSH and 225 IU recombinant LH starting on day 3; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin plus daily FSH anh LH
Description: women receive short-acting Triptorelin 0,05 mg daily starting on day 1 until the hCG injection and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 2.
Study: NCT03681574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Group
Description: Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive placebo concentrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GABA 15mg/kg Group
Description: Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 15mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GABA 30mg/kg Group
Description: Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 30mg/kg.
Study: NCT02932046

Intervention type: DIETARY_SUPPLEMENT
Intervention: Standardized noon meal
Description: The meal is treatment as usual in the specialized somatic stabilization ward for patients with severe anorexia nervosa.
Study: NCT01922050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 Formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 Formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 Formulation 1 Dose X

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 Formulation 1 Dose Y

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 Formulation 2 Dose XX

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 Formulation 2 Dose YY

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Formulation 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Formulation 2
Study: NCT04258241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solution with local anesthetic
Description: Solution of 150 mg of bupivacaine, 0.3 mg of epinephrine and 90 ml of normal saline will be used to perform local infiltration analgesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solution without local anesthetic
Description: Solution of 0.3 mg of epinephrine and 120 ml of normal saline will be used to perform local infiltration analgesia.
Study: NCT01485913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intensive education intervention using a network of involved diabetic patients (peer educators)
Description: the purpose of this methodology is to set up coordinated training and education activities targeting populations with diabetes based on a pragmatic approach (the learning nests methodology) of appropriation and construction of knowledge that takes into account the individual, social, economic, cultural context. This work is being implemented on the basis of group modules specifically designed in their running: are studied the concrete elements of knowledge to mobilize, patients' actions, the role of health the educator, indicators of progress and monitoring during sessions and on the long term. Each patient is gotten to consider the elements involved in his/her disease, and the actions that can be achieved taking into account the feasibility in his/her own context. The education monitoring is envisaged through a data compendium present in the individual booklets that are given to patients at the end of each education session.
Study: NCT04142346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting + moderate intensity breaks
Description: Participants will be followed in a randomized crossover trial undertaken at Faculty of Human Kinetics between April and August 2019. Participants will attend to the laboratory on twelve separate occasions: visit 1 (day 1), baseline assessments for body composition; visit 2 (day 2), cardiorespiratory fitness assessment; visit 3 (day 3), OGTT and the first randomized experimental protocol; visit 4 (day 4), follow-up OGTT; visit 5 (4-6 days after the first experimental protocol), OGTT and the remaining experimental protocol; visit 6 (day following the previous experimental protocol), follow-up OGTT. An additional 6 visits will be performed following the same rational, after a 2-week period of detraining, where participants will be instructed to refrain from structured exercise. The follow-up assessments for body composition and cardiorespiratory fitness will be accomplished after the protocols.
Study: NCT03267264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Nano™ vs Nucleus
Description: Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (BD Nano™) for the second 15-day period or~2. subject's current pen needle (BD Nano™) for the first 15-day period, Nucleus pen needle for the second 15-day period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoFine® vs Nucleus
Description: Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (NovoFine®) for the second 15-day period or~2. subject's current pen needle (NovoFine®) for the first 15-day period, Nucleus pen needle for the second 15-day period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTwist®/NovoFine® Plus vs Nucleus
Description: Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (NovoTwist®/NovoFine Plus®) for the second 15-day period or~2. subject's current pen needle (NovoTwis®t/NovoFine® Plus) for the first 15-day period, Nucleus pen needle for the second 15-day period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus
Description: Subjects will be randomized to~1. Nucleus pen needle for the first 15-day period, or current pen needle (Other Commercially Available Pen Needles) for the second 15-day period or~2. subject's current pen needle (Other Commercially Available Pen Needles) for the first 15-day period, Nucleus pen needle for the second 15-day period
Study: NCT04308681

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986278 Placebo
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BMS-986278 Placebo
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified Dose on Specified Days
Study: NCT01953666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: Rehabilitation program with an occupational therpasit~3 training sessions (one hour) per week for a month (12 sessions)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self - Training at home
Description: Only instructions for a self - training at home
Study: NCT01499875

Intervention type: DRUG
Group type: OTHER
Intervention: Phenoxymethylpenicillin
Description: mixture, 25 or 50 mg/kg taken once.
Study: NCT01542957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Cognitive Behavioral and Dilemma-Focused Therapy
Description: 7 2-hour sessions of Group Cognitive Behavioral Therapy for Depression + 8 individual sessions of a Dilemma-Focused Intervention + 1 3-hour final group session. Manualized.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Depression
Description: Cognitive Behavioral Therapy for Depression. Format: 7 2-hour sessions in group + 8 individual sessions + 1 3-hour final group session. Manualized.
Study: NCT04057781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling (DN)
Description: One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and the subject will lie on a treatment table without moving arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
Study: NCT03687801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online hearing support
Description: The intervention group will follow an online hearing support for five weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The control group will follow standard care during the time the intervention group receives online haring support
Study: NCT03785067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg
Description: 1 capsule taken orally once daily for 36 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1 capsule taken orally once daily for 36 months
Study: NCT01209065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir
Description: Fosamprenavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
Study: NCT03034616

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OLIVA device
Description: OLIVA device is a laparoscopic device with a standard handle and a tip built of 5 parallel razor blades enclosed by protective cap opened by a separate button.~This device will enable to perform shallow slashes on the ovarian cortex following the grasping of the ovary without damaging other abdominal and pelvic organs
Study: NCT01894100

Intervention type: DEVICE
Group type: OTHER
Intervention: Shoe lift correction for leg length inequality
Description: Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoe lift correction for leg length inequality
Description: Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.
Study: NCT02580617

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC
Description: Infusion for Crohn's disease
Study: NCT03169075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise programs
Description: A weekly supervised physical activity session of 60 min at the patient's home is planned for 3 months.~These sessions will be supervised by an educator or physiotherapist trained, with respect to the pathology and the clinical study, specifically for this activity (Fédération Française Sport et Cancer) . The proposed exercises will be normalized and adapted to each patient's profile.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ, Evaluation by a coach VAE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted physical activity
Description: Program based on the recommendations for performing a physical activity. A booklet containing physical activity recommendations will be given to the patients after randomization.~The weekly sessions at the patients home for the experimental group (Program A) must begin as soon as possible within the 15 days after starting oral targeted therapy.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ
Study: NCT03034616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OLIVA device
Description: OLIVA device is a laparoscopic device with a standard handle and a tip built of 5 parallel razor blades enclosed by protective cap opened by a separate button.~This device will enable to perform shallow slashes on the ovarian cortex following the grasping of the ovary without damaging other abdominal and pelvic organs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OLIVA device
Description: OLIVA device is a laparoscopic device with a standard handle and a tip built of 5 parallel razor blades enclosed by protective cap opened by a separate button.~This device will enable to perform shallow slashes on the ovarian cortex following the grasping of the ovary without damaging other abdominal and pelvic organs
Study: NCT04057781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling with Intramuscular electrical stimulation (DNES)
Description: One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject lies on a treatment table without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
Study: NCT02688894

Intervention type: OTHER
Intervention: No treatment is included in this protocol.
Description: Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.~Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists.
Study: NCT02049892

Intervention type: OTHER
Intervention: Metal Ion Levels
Study: NCT01094301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The SPR System
Description: The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
Study: NCT04318470

Intervention type: DIAGNOSTIC_TEST
Intervention: mNGS
Description: Metagenomic next generation sequencing for microbial DNA
Study: NCT02330367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC0010
Description: Phase 1: AC0010 will be administered in escalating dosages in a period of 28-day cycles.~Phase 2: AC0010 will be administered twice-daily at RP2D.
Study: NCT04504071

Intervention type: DRUG
Group type: OTHER
Intervention: Dacomitinib
Description: Patients will receive continuous oral therapy with the study drugs (dacomitinib 45 mg) until disease progression or unacceptable toxicity.
Study: NCT01081444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: effective and active cortical magnetic stimulations

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo rTMS
Description: non active cortical magnetic stimulation
Study: NCT00664378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT997
Description: Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle
Study: NCT04373395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D-CLAG
Description: Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor
Study: NCT04042389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp reminder
Description: The WhatsApp group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email reminder
Description: The Email group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: No messages sent.
Study: NCT01600664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive computer game
Description: Participants will use the interactive computer game installed on a convertible PC

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Convertible PC
Description: Participants will be using the convertible PC without the interactive computer game
Study: NCT01395108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin
Description: oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin
Description: oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin
Description: oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin
Description: oral once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin
Description: oral once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nemonoxacin
Description: oral once daily
Study: NCT00683709

Intervention type: BEHAVIORAL
Intervention: Counselling as Usual
Description: 5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.

Intervention type: BEHAVIORAL
Intervention: CBT
Description: 45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.
Study: NCT03285048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Brain HQ is a computer based cognitive training that uses hierarchical adaptive technology to provide challenging and demanding training that is not too frustrating or discouraging. Training includes auditory and visual sensory training, memory and executive function exercises. The Bridging group is based on similar training programs that focus on self-regulation training, problem focused cognitive behavior therapy and compensatory cognitive strategies.